Why we need to improve serum levels of cholesterol after percutanneous coronary intervention

Czech version

Authors: Ján Murín ¹; Jozef Bulas ¹; Martin Wawruch ²; Alexander Klabník ⁴; Udovít Gašpar ^1,3
Authors‘ workplace: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava ¹; Ústav farmakológie a klinickej farmakológie LF UK v Bratislave ²; Fakulta zdravotníckych vied Univerzita sv. Cyrila a Metoda v Trnave ³; Kardiologická ambulancia, Oravská poliklinika Námestovo ⁴
Published in: AtheroRev 2021; 6(1): 35-39
Category:

Overview

(IHD), mostly during acute coronary syndrome. After PCIs patients still remain at high risk of developing late cardiovascular (CV) events. Although controlling LDL-C may improve outcomes after PCI, practice guidelines do not have specific recommendations on LDL-C management for this subgroup of patients. The aim of the study was to evaluate LDL-C testing and levels after PCI and to assess the association between serum levels of LDL-C and longer-term CV events after PCI. From 10/2011 – 12/2014 in Ontario all patients who received their first PCI were included into registry. Patients who had LDL-C measurement within 6 months after PCI were cathegorized as: < 1.81 mmol/l, 1.81–2.58 mmol/l and ≥ 2.58 mmol/l. The primary composite outcome was CV death, myocardial infarction, coronary revascularization and stroke through december 2016. Among 47 884 included patients, 52 % had LDL-C measured within 6 months of PCI and 57 % had LDL-C < 1.81 mmol/l. After a median 3.2 years the rates of CV events were 55.2/1000 person-years for LDL-C < 1.81 mmol/l subgroup, 60.3/1000 person-years for 1.81–2.58 mmol/l subgroup and 94/1000 person-years for ≥ 2.58 mmol/l subgroup, with hazard ratios 1.17 (2^nd subgroup) and 1.78 (3^rd subgroup) when compared to 1st subgroup of LDL-C. Conclusion: higher levels of LDL-C were associated with an increase of late CV events after PCI. We should improve cholesterol management after PCI.

Keywords:

cholesterol levels – ischemic heart disease – percutaneous coronary intervention – treatment of cholesterol levels

Sources

Alkhouli M, Alqahtani F, Kalra A et al. Trends in characteristics and outcomes of patients undergoing coronary revascularization in the United states 2003–2006. JAMA Netw Open 2020; 3(2): e1921326. Dostupné z DOI: <http://dx.doi.org/10.1001/jamanetworkopen.2019.21326>.
Fanaroff AC, Zakroysky P, Wojdyla D et al. Relationship between operator volume and long-term outcomes after percutaneous coronary intervention. Circulation 2019; 139(4): 458–472. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.033325>.
Frost PH, Verter J, Miller D. Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study. Am Heart J 1987; 113(6): 1356–1364. Dostupné z DOI: <http://dx.doi.org/10.1016/0002–8703(87)90648-x>.
Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322(24): 1700–1707. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199006143222403>.
Farkouh ME, Boden WE, Bittner V et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013; 61(15): 1607–1615. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.01.044>.
Colantonio LD, Huang L, Monda KL et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol 2017; 2(8): 890–895. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2017.0911>.
Gitt AK, Lautsch D, Ferrieres J et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease results from the Dyslipidemia International study II. Atherosclrosis 2017; 266: 158–166. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2017.08.013>.
Kuiper JG, Sanchez RJ, Houben E et al. Use of Lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands. Clin Ther 2017; 39(4):819–827.e1. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clinthera.2017.03.001>.
Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guideline. J Am Coll Cardiol 2019; 73(24): e285-e350. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2018.11.003>. Erratum in Correction. [No authors listed] J Am Coll Cardiol. 2019; 73(24): 3237–3241. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2019.05.013>.
Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines And the Society for Cardiovascular Angiography and Interventionns. J Am Coll Cardiol 2011; 58(24): e44-e122. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.08.007>.
Jellinger PS, Handelsman Y, Rosenblit PD et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017; 23(Suppl 2): 1–87. Dostupné z DOI: <http://dx.doi.org/10.4158/EP171764.APPGL>.
Sud M, Han L, Koh M et al. Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention. J Am Coll Cardiol 2020; 76(12): 1440–1450. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2020.07.033>.
Luca SR, Koh M, Qiu F et al. Stress testing after percutaneous coronary interventions: a population-based study. CMAJ Open 2017; 5(2): E417-E423. Dostupné z DOI: <http://dx.doi.org/10.9778/cmajo.20160159>.
Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2014; 63(25 Pt): 2889–2934. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.11.002>.
Grundy SM, Cleeman JI, Mez CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44(3): 720–732. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2004.07.001>.
Danchin N, Almahmeed W, Al-Rasadi K et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe. The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018; 25(10): 1087–1094. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487318777079>.
Marz W, Dippel FW, Theobald K et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis 2018; 268: 99–107. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2017.11.020>.
Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 2012; 1(6): e001800. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.112.001800>.
Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.
Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307(12): 1302–1309. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2012.366>.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379(22): 2097–2107. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1801174>.
Bhatt DL, Eagle KA, Ohman EM et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304(12): 1350–1357. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2010.1322>.
Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.
Giugliano RP, Pedersen TR, Park J-G et al. Clinical efficacy and safety of achieving very low LDL-Colesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURNIER trial. Lancet 2017; 390(10106): 1962–1971. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)32290–0>.
Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29(2): 151–167. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2012.11.032>.
Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation 2016; 134(24): 1931–1943. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024604>.
Sabatine MS, Giugliano RP, Keech AC et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304(12): 1350–1357. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2010.1322>.